Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis

: Background/Aims: Resolution of liver fibrosis is possible but the identity of the matrix metalloproteinases (MMPs) which degrade the accumulated collagens is uncertain. We examined MMP‐2 and MMP‐14 expression in established and resolving fibrosis to assess their role in resolution of liver fibrosi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Liver international 2004-10, Vol.24 (5), p.492-501
Hauptverfasser: Zhou, Xiaoying, Hovell, Christopher J., Pawley, Susannah, Hutchings, Matthew I., Arthur, Michael J. P., Iredale, John P., Benyon, R. Christopher
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 501
container_issue 5
container_start_page 492
container_title Liver international
container_volume 24
creator Zhou, Xiaoying
Hovell, Christopher J.
Pawley, Susannah
Hutchings, Matthew I.
Arthur, Michael J. P.
Iredale, John P.
Benyon, R. Christopher
description : Background/Aims: Resolution of liver fibrosis is possible but the identity of the matrix metalloproteinases (MMPs) which degrade the accumulated collagens is uncertain. We examined MMP‐2 and MMP‐14 expression in established and resolving fibrosis to assess their role in resolution of liver fibrosis. Methods: MMP and tissue inhibitor of metalloproteinase (TIMP)‐2 expression in liver extracts was examined by ribonuclease protection assay, Western blotting and gelatin zymography. MMP activity was examined by 14C gelatin degradation. Results: In human cirrhotic liver, MMP‐14 mRNA was increased to 230–330% of normal liver expression. Both 63 kDa proenzyme and 60 kDa activated form were present. Cirrhotic livers had 270–320% of normal liver expression of MMP‐2 protein with 20–25% being the 62 Da activated form. Protein and mRNA for MMP‐2 and MMP‐14 progressively increased during 8 weeks of CCl4 treatment in rats. Between 3 and 7 days of resolution from CCl4 liver fibrosis, MMP‐2 and MMP‐14 persisted at elevated levels. Gelatinolytic activity in liver homogenates peaked at 7 days of recovery, being 140% above that in livers at peak fibrosis. Conclusions: Increased expression and activation of MMP‐2 and ‐14 occurs even under conditions of elevated TIMPs during liver fibrogenesis. During liver fibrosis resolution, as TIMP expression decays, the persistence of MMP‐2 and MMP‐14 may permit collagen degradation.
doi_str_mv 10.1111/j.1478-3231.2004.0946.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66969785</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66969785</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4676-9319747cbc254993471bb2ced8b65dbec538ea473a59fa4d0b4baed885ad61a13</originalsourceid><addsrcrecordid>eNqNkc1u1DAUhSMEoqXwCuAVuwQ7_ovFCpW2VBoVhAosLTu5KR6cZLCTNvMcvDBOMxq2eOMr-zvn6t6TZW8ILkg677YFYbLKaUlJUWLMCqyYKOYn2enx_emxLulJ9iLGLcZEKU6eZyeEs6qkrDrN_lzMuwAxuqFHQ4s6MwY3ow5G4_2wC8MIrjcR8hKZvkE5YWgHIbo4RtRMwfV3CEzwe5Q8Bj-NBxuYE-U66JMN8u4eAmqdDUMSPvp07u7niOqhT93sNAIahxXw-4S8zJ61xkd4dbjPsm-XF7fnn_LN56vr8w-bvGZCilxRoiSTta1LzpSiTBJryxqaygreWKg5rcAwSQ1XrWENtsya9Ftx0whiCD3L3q6-ac7fE8RRdy7W4L3pYZiiFkIJJSueQLmCdRohBmj1Lk1nwl4TrJc89FYvu9bL3vWSh17y0HNSvj60mGwHzT_dIYAEvF-BB-dh_7--enP9PRVJna_qFAjMR7UJv7SQVHL94-ZKX6qPePPl9qsW9C-elqw7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66969785</pqid></control><display><type>article</type><title>Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Zhou, Xiaoying ; Hovell, Christopher J. ; Pawley, Susannah ; Hutchings, Matthew I. ; Arthur, Michael J. P. ; Iredale, John P. ; Benyon, R. Christopher</creator><creatorcontrib>Zhou, Xiaoying ; Hovell, Christopher J. ; Pawley, Susannah ; Hutchings, Matthew I. ; Arthur, Michael J. P. ; Iredale, John P. ; Benyon, R. Christopher</creatorcontrib><description>: Background/Aims: Resolution of liver fibrosis is possible but the identity of the matrix metalloproteinases (MMPs) which degrade the accumulated collagens is uncertain. We examined MMP‐2 and MMP‐14 expression in established and resolving fibrosis to assess their role in resolution of liver fibrosis. Methods: MMP and tissue inhibitor of metalloproteinase (TIMP)‐2 expression in liver extracts was examined by ribonuclease protection assay, Western blotting and gelatin zymography. MMP activity was examined by 14C gelatin degradation. Results: In human cirrhotic liver, MMP‐14 mRNA was increased to 230–330% of normal liver expression. Both 63 kDa proenzyme and 60 kDa activated form were present. Cirrhotic livers had 270–320% of normal liver expression of MMP‐2 protein with 20–25% being the 62 Da activated form. Protein and mRNA for MMP‐2 and MMP‐14 progressively increased during 8 weeks of CCl4 treatment in rats. Between 3 and 7 days of resolution from CCl4 liver fibrosis, MMP‐2 and MMP‐14 persisted at elevated levels. Gelatinolytic activity in liver homogenates peaked at 7 days of recovery, being 140% above that in livers at peak fibrosis. Conclusions: Increased expression and activation of MMP‐2 and ‐14 occurs even under conditions of elevated TIMPs during liver fibrogenesis. During liver fibrosis resolution, as TIMP expression decays, the persistence of MMP‐2 and MMP‐14 may permit collagen degradation.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/j.1478-3231.2004.0946.x</identifier><identifier>PMID: 15482348</identifier><language>eng</language><publisher>Oxford, UK: Munksgaard International Publishers</publisher><subject>Adult ; Animals ; collagenase ; Disease Models, Animal ; Fibrosis - metabolism ; Fibrosis - pathology ; hepatic stellate cell ; Humans ; Liver Cirrhosis, Experimental - enzymology ; Liver Cirrhosis, Experimental - pathology ; liver fibrosis ; Male ; matrix metalloproteinase ; Matrix Metalloproteinase 2 - metabolism ; Matrix Metalloproteinases, Membrane-Associated ; Metalloendopeptidases - genetics ; Metalloendopeptidases - metabolism ; Middle Aged ; Rats ; Rats, Sprague-Dawley ; Recovery of Function ; RNA, Messenger - metabolism ; tissue inhibitor of metalloproteinase ; Tissue Inhibitor of Metalloproteinase-2 - metabolism</subject><ispartof>Liver international, 2004-10, Vol.24 (5), p.492-501</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4676-9319747cbc254993471bb2ced8b65dbec538ea473a59fa4d0b4baed885ad61a13</citedby><cites>FETCH-LOGICAL-c4676-9319747cbc254993471bb2ced8b65dbec538ea473a59fa4d0b4baed885ad61a13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1478-3231.2004.0946.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1478-3231.2004.0946.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15482348$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhou, Xiaoying</creatorcontrib><creatorcontrib>Hovell, Christopher J.</creatorcontrib><creatorcontrib>Pawley, Susannah</creatorcontrib><creatorcontrib>Hutchings, Matthew I.</creatorcontrib><creatorcontrib>Arthur, Michael J. P.</creatorcontrib><creatorcontrib>Iredale, John P.</creatorcontrib><creatorcontrib>Benyon, R. Christopher</creatorcontrib><title>Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>: Background/Aims: Resolution of liver fibrosis is possible but the identity of the matrix metalloproteinases (MMPs) which degrade the accumulated collagens is uncertain. We examined MMP‐2 and MMP‐14 expression in established and resolving fibrosis to assess their role in resolution of liver fibrosis. Methods: MMP and tissue inhibitor of metalloproteinase (TIMP)‐2 expression in liver extracts was examined by ribonuclease protection assay, Western blotting and gelatin zymography. MMP activity was examined by 14C gelatin degradation. Results: In human cirrhotic liver, MMP‐14 mRNA was increased to 230–330% of normal liver expression. Both 63 kDa proenzyme and 60 kDa activated form were present. Cirrhotic livers had 270–320% of normal liver expression of MMP‐2 protein with 20–25% being the 62 Da activated form. Protein and mRNA for MMP‐2 and MMP‐14 progressively increased during 8 weeks of CCl4 treatment in rats. Between 3 and 7 days of resolution from CCl4 liver fibrosis, MMP‐2 and MMP‐14 persisted at elevated levels. Gelatinolytic activity in liver homogenates peaked at 7 days of recovery, being 140% above that in livers at peak fibrosis. Conclusions: Increased expression and activation of MMP‐2 and ‐14 occurs even under conditions of elevated TIMPs during liver fibrogenesis. During liver fibrosis resolution, as TIMP expression decays, the persistence of MMP‐2 and MMP‐14 may permit collagen degradation.</description><subject>Adult</subject><subject>Animals</subject><subject>collagenase</subject><subject>Disease Models, Animal</subject><subject>Fibrosis - metabolism</subject><subject>Fibrosis - pathology</subject><subject>hepatic stellate cell</subject><subject>Humans</subject><subject>Liver Cirrhosis, Experimental - enzymology</subject><subject>Liver Cirrhosis, Experimental - pathology</subject><subject>liver fibrosis</subject><subject>Male</subject><subject>matrix metalloproteinase</subject><subject>Matrix Metalloproteinase 2 - metabolism</subject><subject>Matrix Metalloproteinases, Membrane-Associated</subject><subject>Metalloendopeptidases - genetics</subject><subject>Metalloendopeptidases - metabolism</subject><subject>Middle Aged</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Recovery of Function</subject><subject>RNA, Messenger - metabolism</subject><subject>tissue inhibitor of metalloproteinase</subject><subject>Tissue Inhibitor of Metalloproteinase-2 - metabolism</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1u1DAUhSMEoqXwCuAVuwQ7_ovFCpW2VBoVhAosLTu5KR6cZLCTNvMcvDBOMxq2eOMr-zvn6t6TZW8ILkg677YFYbLKaUlJUWLMCqyYKOYn2enx_emxLulJ9iLGLcZEKU6eZyeEs6qkrDrN_lzMuwAxuqFHQ4s6MwY3ow5G4_2wC8MIrjcR8hKZvkE5YWgHIbo4RtRMwfV3CEzwe5Q8Bj-NBxuYE-U66JMN8u4eAmqdDUMSPvp07u7niOqhT93sNAIahxXw-4S8zJ61xkd4dbjPsm-XF7fnn_LN56vr8w-bvGZCilxRoiSTta1LzpSiTBJryxqaygreWKg5rcAwSQ1XrWENtsya9Ftx0whiCD3L3q6-ac7fE8RRdy7W4L3pYZiiFkIJJSueQLmCdRohBmj1Lk1nwl4TrJc89FYvu9bL3vWSh17y0HNSvj60mGwHzT_dIYAEvF-BB-dh_7--enP9PRVJna_qFAjMR7UJv7SQVHL94-ZKX6qPePPl9qsW9C-elqw7</recordid><startdate>200410</startdate><enddate>200410</enddate><creator>Zhou, Xiaoying</creator><creator>Hovell, Christopher J.</creator><creator>Pawley, Susannah</creator><creator>Hutchings, Matthew I.</creator><creator>Arthur, Michael J. P.</creator><creator>Iredale, John P.</creator><creator>Benyon, R. Christopher</creator><general>Munksgaard International Publishers</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200410</creationdate><title>Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis</title><author>Zhou, Xiaoying ; Hovell, Christopher J. ; Pawley, Susannah ; Hutchings, Matthew I. ; Arthur, Michael J. P. ; Iredale, John P. ; Benyon, R. Christopher</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4676-9319747cbc254993471bb2ced8b65dbec538ea473a59fa4d0b4baed885ad61a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Animals</topic><topic>collagenase</topic><topic>Disease Models, Animal</topic><topic>Fibrosis - metabolism</topic><topic>Fibrosis - pathology</topic><topic>hepatic stellate cell</topic><topic>Humans</topic><topic>Liver Cirrhosis, Experimental - enzymology</topic><topic>Liver Cirrhosis, Experimental - pathology</topic><topic>liver fibrosis</topic><topic>Male</topic><topic>matrix metalloproteinase</topic><topic>Matrix Metalloproteinase 2 - metabolism</topic><topic>Matrix Metalloproteinases, Membrane-Associated</topic><topic>Metalloendopeptidases - genetics</topic><topic>Metalloendopeptidases - metabolism</topic><topic>Middle Aged</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Recovery of Function</topic><topic>RNA, Messenger - metabolism</topic><topic>tissue inhibitor of metalloproteinase</topic><topic>Tissue Inhibitor of Metalloproteinase-2 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Xiaoying</creatorcontrib><creatorcontrib>Hovell, Christopher J.</creatorcontrib><creatorcontrib>Pawley, Susannah</creatorcontrib><creatorcontrib>Hutchings, Matthew I.</creatorcontrib><creatorcontrib>Arthur, Michael J. P.</creatorcontrib><creatorcontrib>Iredale, John P.</creatorcontrib><creatorcontrib>Benyon, R. Christopher</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Xiaoying</au><au>Hovell, Christopher J.</au><au>Pawley, Susannah</au><au>Hutchings, Matthew I.</au><au>Arthur, Michael J. P.</au><au>Iredale, John P.</au><au>Benyon, R. Christopher</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2004-10</date><risdate>2004</risdate><volume>24</volume><issue>5</issue><spage>492</spage><epage>501</epage><pages>492-501</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>: Background/Aims: Resolution of liver fibrosis is possible but the identity of the matrix metalloproteinases (MMPs) which degrade the accumulated collagens is uncertain. We examined MMP‐2 and MMP‐14 expression in established and resolving fibrosis to assess their role in resolution of liver fibrosis. Methods: MMP and tissue inhibitor of metalloproteinase (TIMP)‐2 expression in liver extracts was examined by ribonuclease protection assay, Western blotting and gelatin zymography. MMP activity was examined by 14C gelatin degradation. Results: In human cirrhotic liver, MMP‐14 mRNA was increased to 230–330% of normal liver expression. Both 63 kDa proenzyme and 60 kDa activated form were present. Cirrhotic livers had 270–320% of normal liver expression of MMP‐2 protein with 20–25% being the 62 Da activated form. Protein and mRNA for MMP‐2 and MMP‐14 progressively increased during 8 weeks of CCl4 treatment in rats. Between 3 and 7 days of resolution from CCl4 liver fibrosis, MMP‐2 and MMP‐14 persisted at elevated levels. Gelatinolytic activity in liver homogenates peaked at 7 days of recovery, being 140% above that in livers at peak fibrosis. Conclusions: Increased expression and activation of MMP‐2 and ‐14 occurs even under conditions of elevated TIMPs during liver fibrogenesis. During liver fibrosis resolution, as TIMP expression decays, the persistence of MMP‐2 and MMP‐14 may permit collagen degradation.</abstract><cop>Oxford, UK</cop><pub>Munksgaard International Publishers</pub><pmid>15482348</pmid><doi>10.1111/j.1478-3231.2004.0946.x</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1478-3223
ispartof Liver international, 2004-10, Vol.24 (5), p.492-501
issn 1478-3223
1478-3231
language eng
recordid cdi_proquest_miscellaneous_66969785
source Wiley Online Library - AutoHoldings Journals; MEDLINE
subjects Adult
Animals
collagenase
Disease Models, Animal
Fibrosis - metabolism
Fibrosis - pathology
hepatic stellate cell
Humans
Liver Cirrhosis, Experimental - enzymology
Liver Cirrhosis, Experimental - pathology
liver fibrosis
Male
matrix metalloproteinase
Matrix Metalloproteinase 2 - metabolism
Matrix Metalloproteinases, Membrane-Associated
Metalloendopeptidases - genetics
Metalloendopeptidases - metabolism
Middle Aged
Rats
Rats, Sprague-Dawley
Recovery of Function
RNA, Messenger - metabolism
tissue inhibitor of metalloproteinase
Tissue Inhibitor of Metalloproteinase-2 - metabolism
title Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T15%3A44%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20matrix%20metalloproteinase-2%20and%20-14%20persists%20during%20early%20resolution%20of%20experimental%20liver%20fibrosis%20and%20might%20contribute%20to%20fibrolysis&rft.jtitle=Liver%20international&rft.au=Zhou,%20Xiaoying&rft.date=2004-10&rft.volume=24&rft.issue=5&rft.spage=492&rft.epage=501&rft.pages=492-501&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/j.1478-3231.2004.0946.x&rft_dat=%3Cproquest_cross%3E66969785%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66969785&rft_id=info:pmid/15482348&rfr_iscdi=true